Recent Updates
Recently added Catalysts
CGON Positive Sentiment

TARGETED ONCOLOGY

Tuesday, July 25, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology has announced positive initial results from its CORE-1008 Phase 2 trial, which evaluates an intravesical combination therapy for patients who are high-risk and either BCG-exposed or BCG-unresponsive. The company is also set to present at various upcoming investor conferences, showcasing its commitment to advancing treatment options in oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • CG Oncology reports positive results from CORE-1008 trial.
  • The trial focuses on high-risk BCG-exposed patients.
  • Company's participation in investor conferences highlights growth.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Jul 25, 2023 | in-the-news

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What are the results of the CORE-1008 trial?

The CORE-1008 trial reported positive initial results for high-risk BCG-exposed patients.

What type of therapy is being evaluated in CORE-1008?

The trial evaluates an intravesical combination therapy.

When will CG Oncology present at investor conferences?

CG Oncology is scheduled to present at upcoming investor conferences in June.

Who are the recipients of the NMIBC Research Fellowship Award?

CG Oncology announced the award recipients of the second annual NMIBC Research Fellowship.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology CORE-1008 Phase 2 trial BCG-exposed patients oncology
Last updated: Jul 25, 2023

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →